Radiation for prostate cancer that remains active after hormone therapy
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether adding radiation to the prostate and to any remaining cancer spots can help when hormone therapy alone hasn't fully controlled the cancer. It is for men whose PSA remains slightly elevated after six months of initial hormone treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have prostate cancer that has spread to at least 4 spots in your bones (with or without lymph node spread) when first diagnosed.
- You have been on a combination of hormone therapy (ADT plus an ARPI) for at least 6 months.
- Your PSA level is still above 0.2 ng/ml after those 6 months.
- You have no cancer spread to internal organs like the liver or lungs.
- After 6 months of hormone therapy, you have fewer than 16 spots of cancer in your bones or lymph nodes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special PET scan (POSLUMA) before and after radiation to see if it helps treat prostate cancer that has spread to a few spots outside the pelvis. It's for men whose cancer still responds to hormone therapy and who have not had widespread spread.
This trial tests whether adding a PSMA-targeted radioactive medicine (Lu-PSMA) to focused stereotactic radiation to a few prostate cancer spots works better than radiation alone. It may help people with limited, asymptomatic spread of prostate cancer by improving cancer control while carefully monitoring side effects.
This trial tests whether using a specialized PSMA PET scan to guide radiation can better treat prostate cancer that returns after prostate surgery. It targets the “prostate bed” area with a shorter, stronger radiation schedule (hypofractionated) to control rising PSA levels.
This trial is testing whether giving radiation to all spots of cancer that show up on a PSMA PET scan works better than giving radiation only to the main tumor in the prostate. It is for men whose prostate cancer has spread to a few other places (up to 10 spots).
This trial tests a combination of two treatments for men with prostate cancer that has spread to a small number of sites: a radioactive injection (177Lu-PSMA-617) that targets cancer cells, plus hormone-blocking medication. The goal is to control the cancer and delay progression.
This Phase 1/2 trial tests a PSMA-targeted radioligand treatment (a drug that delivers radiation to prostate cancer cells) in men with metastatic castration-resistant prostate cancer that has gotten worse despite standard hormone therapies. It’s designed to see how the treatment works and whether it can help shrink or control cancer, while also studying safety and dosing.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.